Various prescription drug transaction, coverage, and data provisions modifications
Comm report: To pass as amended and re-refer to
Email me when SF 4419 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SF 4419. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill would require drug manufacturers, pharmacies, PBMs and wholesale distributors to report detailed pricing and usage data for drugs deemed of substantial public interest. It also standardizes electronic prior‑authorization requests, tightens HMO network‑notification requirements, and expands definitions to include stand‑alone dental plans and biosimilars. The measures aim to increase transparency and simplify administration, but the bill did not pass.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SF 4419
3 free questions a day, no accountHearings
- Commerce and Consumer ProtectionCommerce and Consumer Protection · Mar 27, 2026
History
- Comm report: To pass as amended and re-refer to Health and Human Services
- Comm report: To pass as amended and re-refer to Commerce and Consumer Protection
- Referred to Health and Human Services
- Introduction and first reading
Sponsors
- Wiklund · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SF 4419 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SF 4419 freeOr ask your AI assistant about SF 4419 directly:
Add to Claude, ChatGPT or Cursor